Peter Rahmer Biography and Net Worth

Insider of Relay Therapeutics

As Chief Corporate Development Officer, Pete Rahmer leads business development, capital raising, investor relations and external communications. Prior to Relay Therapeutics, Pete was the founder and managing partner of Endurance Advisors, a biotech-focused investor relations and capital markets advisory firm. Prior to Endurance, he was a managing director at the Trout Group and headed the firm’s West Coast practice. Earlier in his career, Pete was part of Thomson Financial’s Biotechnology Capital Markets Intelligence team.

Over the past 17 years, Pete has advised more than 50 companies in capital raising, strategy and investor relations, helping clients raise over $3 billion through capital market offerings over his tenure.

Pete holds a B.A. in economics from St. Lawrence University and an MBA from the Rochester Institute of Technology.

What is Peter Rahmer's net worth?: The estimated net worth of Peter Rahmer is at least $2.70 million as of October 29th, 2025. Rahmer owns 337,469 shares of Relay Therapeutics stock worth more than $2,699,752 as of December 5th. This net worth estimate does not reflect any other investments that Rahmer may own. Learn More about Peter Rahmer's net worth.
How do I contact Peter Rahmer?: The corporate mailing address for Rahmer and other Relay Therapeutics executives is 399 BINNEY STREET 2ND FLOOR, CAMBRIDGE MA, 02139. Relay Therapeutics can also be reached via phone at 617-370-8837 and via email at [email protected]. Learn More on Peter Rahmer's contact information.
Has Peter Rahmer been buying or selling shares of Relay Therapeutics?: During the last quarter, Peter Rahmer has sold $299,949.15 in Relay Therapeutics stock. Most recently, Peter Rahmer sold 21,394 shares of the business's stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $7.50, for a transaction totalling $160,455.00. Following the completion of the sale, the insider now directly owns 337,469 shares of the company's stock, valued at $2,531,017.50. Learn More on Peter Rahmer's trading history.
Who are Relay Therapeutics' active insiders?: Relay Therapeutics' insider roster includes Brian Adams (General Counsel), Donald Bergstrom (Insider), Thomas Catinazzo (SVP), Sanjiv Patel (President & Chief Executive Officer), Andy Porter (Insider), and Peter Rahmer (Insider). Learn More on Relay Therapeutics' active insiders.
Are insiders buying or selling shares of Relay Therapeutics?: In the last twelve months, insiders at the sold shares 33 times. They sold a total of 968,861 shares worth more than $4,432,693.30. The most recent insider tranaction occured on November, 3rd when CEO Sanjiv Patel sold 62,073 shares worth more than $434,511.00. Insiders at Relay Therapeutics own 4.9% of the company. Learn More about insider trades at Relay Therapeutics.
Information on this page was last updated on 11/3/2025.

Peter Rahmer Insider Trading History at Relay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/29/2025	Sell	21,394	$7.50	$160,455.00	337,469
10/28/2025	Sell	19,135	$7.29	$139,494.15	358,863
7/29/2025	Sell	15,724	$3.68	$57,864.32	377,998
7/28/2025	Sell	1,359	$3.74	$5,082.66	393,722
4/30/2025	Sell	10,739	$3.00	$32,217.00	390,081
4/28/2025	Sell	1,364	$3.17	$4,323.88	400,820
1/30/2025	Sell	17,250	$4.42	$76,245.00	402,431
1/28/2025	Sell	1,673	$4.63	$7,745.99	307,081
1/6/2025	Sell	16,576	$4.45	$73,763.20	308,754
1/2/2025	Sell	32,156	$4.15	$133,447.40	357,507
10/28/2024	Sell	1,621	$6.06	$9,823.26	390,063
7/31/2024	Sell	13,708	$8.19	$112,268.52	391,929
7/29/2024	Sell	13,523	$8.54	$115,486.42	420,765
6/5/2024	Sell	20,450	$7.06	$144,377.00	432,425
6/3/2024	Sell	19,864	$6.47	$128,520.08	493,470
4/29/2024	Sell	1,345	$6.38	$8,581.10	513,334
1/29/2024	Sell	1,651	$9.64	$15,915.64	514,977
12/27/2023	Sell	244	$11.51	$2,808.44	316,628
10/30/2023	Sell	1,354	$6.03	$8,164.62	316,872
7/28/2023	Sell	1,352	$11.80	$15,953.60	316,808
4/28/2023	Sell	739	$11.16	$8,247.24	157,504
3/27/2023	Sell	297	$15.36	$4,561.92	158,243
1/30/2023	Sell	740	$21.56	$15,954.40	158,540

Peter Rahmer Buying and Selling Activity at Relay Therapeutics

Relay Therapeutics Company Overview

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $8.00

$7.69

$8.09

50 Day Range

MA: $6.66

$5.17

$8.17

2 Week Range

Now: $8.00

$1.77

$8.36

Volume

1,205,788 shs

Average Volume

2,138,458 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.5